In short
Clinical trials investigating Idarubicin Hydrochloride are studying how it is used in treatment plans for several cancers, especially leukemia. These trials look at safety, response rates, survival, and other outcomes in adults, children, and older patients with different disease types.
Key points
- Clinical trials investigating Idarubicin Hydrochloride are mainly focused on blood cancers, especially acute myeloid leukemia and acute lymphoblastic leukemia, with one study in hepatocellular carcinoma. The studies include Phase 1 dose-finding research, Phase 2 response studies, and larger Phase 3 comparison trials. Target groups include adults, children, adolescents, older patients, and people with newly diagnosed, relapsed, refractory, or high-risk disease. Some trials also focus on specific genetic subgroups, such as NPM1-mutated AML, FLT3-ITD negative AML, KMT2A or NPM1 alterations, and Ph-like or very high-risk ALL. The main outcomes being measured include safety, dose-limiting toxicity, MRD negativity, disease control, event-free survival, and overall survival.
Trial overview
The trial data show that Idarubicin Hydrochloride is being studied in interventional trials, which means patients receive a planned treatment and the researchers measure the results. Most studies focus on blood cancers, especially acute myeloid leukemia and acute lymphoblastic leukemia, but one study also includes hepatocellular carcinoma.
The studies are authorised and include Phase 1, Phase 2, and Phase 3 trials. Enrollment ranges from small early studies to large multicenter trials with more than 1,000 participants.
Who is being studied
Several trials include newly diagnosed patients, meaning people who have just been found to have the disease. Other studies focus on relapsed disease, which means the cancer returned after treatment, or refractory disease, which means the cancer did not respond well enough to treatment.
The trial group also includes children, adolescents, adults, and older patients. Some studies look at special subgroups, such as patients with KMT2A or NPM1 alterations, FLT3-ITD negative AML, NPM1-mutated AML, very high-risk T-cell ALL, or Philadelphia chromosome-positive or negative ALL.
Trial phases and goals
Phase 1 studies in the data mainly focus on safety, tolerability, and dose finding. One Phase 1 study in older patients with non-favorable AML looks for dose-limiting toxicity, maximal tolerated dose, and the recommended phase II dose.
Phase 2 trials look more at whether the treatment works in a chosen patient group. For example, one Phase 2 study in hepatocellular carcinoma measures disease control rate at 4 months, and another Phase 2 study in very high-risk T-ALL measures MRD negativity after induction treatment.
Phase 3 trials are larger and compare treatment strategies. These studies compare different chemotherapy backbones, add-on medicines, or consolidation plans to see which approach gives better outcomes for survival, relapse control, or treatment burden.
Main outcomes being measured
The studies measure several key outcomes, including adverse events, which are unwanted medical problems during treatment, and dose-limiting toxicities, which are side effects that may stop dose increases.
Many leukemia studies measure MRD negativity, meaning no measurable residual disease is found with the test used in the study. Other important outcomes are event-free survival, overall survival, disease control rate, and complete response or remission-related measures.
Some trials also use composite endpoints, which means more than one event is counted in the main result. For example, one study counts relapse, death, toxicity, and resistance as part of the main endpoint.
Key studies involving Idarubicin Hydrochloride
One Phase 1 study in newly diagnosed non-favorable AML in older patients tests Idarubicin Hydrochloride with cytarabine and sulfasalazine. Its main goals are to find a safe dose, identify the maximal tolerated dose, and look for early signs of anti-leukemia activity.
Another Phase 2 study in hepatocellular carcinoma on cirrhosis evaluates an Idarubicin Hydrochloride and Lipiodol emulsion and measures disease control at 4 months using mRECIST criteria, which is a standard way to judge tumor response on scans.
A large Phase 3 AML trial in newly diagnosed FLT3-ITD negative disease compares quizartinib plus standard chemotherapy with placebo plus standard chemotherapy, and Idarubicin Hydrochloride is part of the chemotherapy backbone. The main outcome is overall survival.
In a Phase 3 trial for children and adolescents with AML, Idarubicin Hydrochloride appears in one treatment group among several strategies for de novo, relapsed, and transplant-related settings. The study uses event-free survival, overall survival, and a composite endpoint depending on the group.
Another Phase 2 trial in very high-risk T-lineage ALL studies daratumumab added to a national treatment program and measures MRD negativity after the first induction cycle. A separate Phase 3 study in NPM1-mutated AML tests revumenib with intensive chemotherapy and measures event-free survival and MRD-negative complete remission.
What these trials mean for patients
These studies show that Idarubicin Hydrochloride is being used as part of broader cancer treatment plans, not usually as a single study drug. The research is trying to learn which combinations work best for specific patient groups, including people with newly diagnosed disease, high-risk disease, or disease that has come back.
Because the studies use different phases and different outcome measures, they are asking different questions about treatment. Some are mainly about safety and dosing, while others are about survival, remission, or control of the cancer over time.